D

Dynavax Technologies Corp
D

DVAX

12.840
USD
0.12
(0.94%)
مفتوح الان
حجم التداول
28,898
الربح لكل سهم
0
العائد الربحي
-
P/E
86
حجم السوق
1,687,876,563
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ALT
    -0.55500
    (-6.71%)
    7.72000 USD
    B
    BCRX
    0.17500
    (2.31%)
    7.74500 USD
    E
    EBS
    0.01000
    (0.12%)
    8.10000 USD
    GSK
    GSK
    0.365
    (1.09%)
    33.960 USD
    I
    INO
    -0.04000
    (-2.19%)
    1.79000 USD
    MRNA
    MRNA
    -0.055
    (-0.14%)
    39.305 USD
    N
    NVAX
    -0.18000
    (-2.06%)
    8.54000 USD
    S
    SVA
    0.000000
    (0.00%)
    0.000000 USD
    TAK
    TAK
    0.025
    (0.19%)
    13.125 USD
    V
    VSTM
    -0.20000
    (-4.76%)
    4.00000 USD
    المزيد
الأخبار
المقالات

العنوان: Dynavax Technologies Corp

القطاع: Healthcare
الصناعة: Drug Manufacturers - Specialty & Generic
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.